Agios licenses oral blood disorder drug from Oscotec in $165M deal
Agios Pharmaceuticals (NASDAQ:AGIO) has acquired an exclusive global license for Oscotec's cevidoplenib, an experimental oral treatment for a rare blood disorder, betting the asset can capture up to $1 billion in peak U.S. sales despite recently missing the main goal of a mid-stage trial.










